Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707046 | 0.75 | — | — | |
| SCHEMBL31238696 | 0.69 | KMT2A (0.42) | KMT2A | |
| SCHEMBL20142951 | 0.65 | KMT2A (0.39) | KMT2A | |
| SCHEMBL20138684 | 0.65 | KMT2A (0.39) | KMT2A | |
| SCHEMBL18695225 | 0.64 | — | — | |
| SCHEMBL31642315 | 0.61 | KMT2A (0.39) | KMT2A | |
| SCHEMBL13071968 | 0.61 | HSD17B10 (0.33) | — | |
| SCHEMBL25325933 | 0.60 | — | — | |
| SCHEMBL19887461 | 0.60 | BRD4 (0.30) | — | |
| SCHEMBL24610324 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4619104-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | Novartis AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240360118-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4424370-A2 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1LOCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-3894411-B1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2022249060-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022122800-A1 | PROCESS FOR THE PREPARATION 4-(3,5-DIFLUOROPHENYL)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3- AZABICYCLO[3.2.1]OCTAN-8-YL]-6,7-DIHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-16 | — | — | WO | disclosed |
| CN-109790149-B | Phenoxytriazoles | 豪夫迈·罗氏有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11319314-B2 | Phenoxytriazoles | HOFFMANN-LA ROCHE INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20210309653-A1 | PHENOXYTRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113179641-A | 7-phenoxy-N- (3-azabicyclo [3.2.1] octan-8-yl) -6, 7-dihydro-5H-pyrrolo [1, 2-B ] [1, 2, 4] triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | 豪夫迈·罗氏有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3538516-B1 | PHENOXYTRIAZOLES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538516-A1 | PHENOXYTRIAZOLES | F. Hoffmann-La Roche AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087018-A1 | PHENOXYTRIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309653-A1 | PHENOXYTRIAZOLES | HTT, PSEN1, APP | KMT2A 637/4885 |
| US-20240360118-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | KMT2A 887/4885 |
| US-20220056036-A1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, APP | KMT2A 2856/4885 |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | KMT2A 943/4885 |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | BACE1, PSEN1, APP | KMT2A 3048/4885 |
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | KMT2A 605/4885 |
| US-11319314-B2 | Phenoxytriazoles | HTT, APP, PSEN1 | KMT2A 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.